Results 171 to 180 of about 2,463,176 (288)

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

<i>Chlamydia trachomatis</i>-Specific Antibodies and In Vitro Fertilization Outcome. [PDF]

Biomedicines
Djordjevic N, Todorovic A, Sazdanovic P, Sazdanovic M, Sorak M, Gavrilovic A, Parandilovic A, Garalejic E, Vujovic M, Matic S, Popovic S, Baskic D.   +11 more
europepmc   +1 more source

Halothane specific antibody [PDF]

Anaesthesia, 1987
openaire   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Tat-specific antibodies associated with better HIV-associated motor function. [PDF]

Sci Rep
Hioe CE, Yengo CK, Liu X, Davis R, Enyindah-Asonye G, Klingler J, Tang AF, Bandres JC, Ganesan A, Lalani T, Yabes J, Agan BK, Liu X, Volsky DJ, Morgello S, Robinson-Papp J.   +15 more
europepmc   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Recipient-specific antibodies in HSCT: current knowledge and future perspectives. [PDF]

Front Immunol
Pasi A, Prezioso CT, Comoli P, Sbarsi I, Cacciatore R, Giorgiani G, Recupero S, Bergamaschi P, Torchio M, Taurino A, Losi G, Zerbi C, Bianchessi A, Defrancesco I, Polverelli N, Zecca M, Perotti CG.   +16 more
europepmc   +1 more source

Heme-Specific Antibodies

Science Trends, 2017
Zélia Gouveia, Miguel Soares
openaire   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Epitope-specific antibodies can distinguish between soluble huntingtin exon-1 and its diverse cellular aggregates. [PDF]

J Biol Chem
Lugo J, Xu H, Chen J, Khoshnan A, Langen R.   +4 more
europepmc   +1 more source